老年腰椎间盘突出症的手术治疗

目的 探讨老年腰椎间盘突出症的特点与手术治疗效果.方法 对62例老人腰椎间盘突出症患者的临床与病理特点进行分析.均行腰椎后路椎板减压髓核摘除术,其中小切口开窗35例,半椎板切除20例,全椎板切除7例,根据手术前后JOA评分评价手术疗效.结果 老年腰椎间盘突出症病理以髓核组织的脱水,纤维环的破裂,小关节囊、周围韧带及软骨终板退变为主要特点.临床特点为下肢疼痛多发,腰部活动受限较多;双下肢神经系统检查肌力下降明显,生理反射改变明显.62例平均随访1.9年,JOA评分术后平均改善率为68.9%,手术前后JOA评分比较差异有显著性意义(P＜0.05).结论 老年腰椎间盘突出症患者病程长,体征多,病理改变明显,行腰椎后路椎板减压髓核摘除术,手术效果满意.     

随机微分方程特征值期望的上界估计

利用变分原理,从不同角度,讨论了随机微分方程特征问题特征值的性质,给出了其期望值的两个上界估计式。     

戊四氮诱发大鼠全身强直-阵挛性癫痫发作诱导丘脑c-fos癌基因表达

首次运用Fos癌蛋白抗体免疫组化法详细研究了戊四氮诱发大鼠全身强直-阵挛性癫痫发作诱导丘脑c-fos癌基因表达的动态分布。主要结果是:腹腔内注入戊四氮诱导大鼠癫痫发作后0.5h,丘脑室旁核出现低密度的Fos-免疫阳性(Fos-ir)细胞核标记;3h时,中等密度的Fos-ir标记扩布至大部分丘脑中线和板内核群及网状核;6h时,所有上述丘脑核群的Fos-ir标记普遍增为中等至高密度。结合文献报道,上述结果提示:丘脑室旁核很可能是戊四氮诱发大鼠全身强直-阵挛性癫痫发作的重要起源部位之一;丘脑中线和板内核群及网状核很可能在此种癫痫发作的病理生理机制中起重要作用。     

Comparative study on healing process between vascularized and non-vascularized autogenous bone grafts]

This study made a histological comparison (light microscope and transmission electron microscope) between vascularized bone graft (VBG) and non-vascularized bone graft (NVBG) in mandible of dog.The study showed:the healing process of VBG was the same as that of bone fracture.The "creeping substitution" process of NVBG was imbued with the inflammation induced by dead bone.There was no significat difference on the bone union between VBG and NVBG perhaps for the recipient region was better vascularized.     

米氮平治疗神经性厌食症的疗效对照研究

目的：观察米氮平对神经性厌食症的疗效。方法：42例符合CCMD-3神经性厌食症患者被随机分成2组，分别给予米氮平和5-羟色胺再摄取抑制剂（SSRIs）治疗12周，而后随访12周。比较患者治疗前后的体重变化、汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA）评分及药物不良反应。结果：共38例患者完成治疗全过程，其中米氮平组20例，SSRIs组18例。在治疗6周时，米氮平组的体重增加大于SSRIs组，差异有显著性（P〈0．01）；治疗12周时，两组体重增加值差异没有显著性。治疗后两组HAMD和HAMA评分均明显减低（P〈0．01），但两组间差异无显著性（P〉0．05）。两组均未出现严重的药物不良反应，主要不良反应SSRIs组为胃肠道不适，米氮平有嗜睡、体重增加等。结论：米氮平能明显提高神经性厌食症患者的食欲和体重，改善焦虑抑郁情绪，依从性好，起效时间早于SSRIs，值得在临床上选用。     

白细胞介素—1对大鼠下丘脑室旁核Fos癌蛋白和CRF的诱导作用

将白细胞介素-1(IL)注入大鼠侧脑室,用Fos癌蛋白抗体免疫组化法检测了下丘脑室旁核的激活神经元:大量位于含促肾上腺皮质激素释放因子(CRF)相应区域的室旁核小细胞部神经元呈Fos免疫强阳性。Fos和CRF的免疫双染色显示了许多Fos免疫阳性神经元也呈CRF免疫阳性。此外,在IL-1注射动物中,CRF的免疫阳性显著加强,提示CRF合成增加。     

Study of severe hepatitis treated with a hybrid artificial liver support system

Artificial liver support system (ALSS) has been used to treat hepatic failure and has significantly decreased the mortality. TECA hybrid artificial liver support system (TECA-HALSS), which combines the hollow fiber bioreactor with a plasma exchange circuit, was used to assess the efficacy, safety and feasibility in treating severe hepatitis patients. The hybrid artificial liver support system (HALSS) consists of a bioreactor containing more than 5 x10(9) porcine hepatocytes and plasma exchange device. Fifteen patients with severe hepatitis were treated with this hybrid system. All patients experienced a reduction in symptoms such as fatigue, abdominal distention or ascites. After each treatment serum total bilirubin decreased markedly while prothrombin activity increased. There were ten patients whose progress of hepatocyte necrosis was stopped after HALSS treatment, and finally they recovered completely. One patient received liver transplantation after HALSS therapy and survived. No serious adverse events were noted in the fifteen patients.